Latest News

Eppendorf and BioLabs Expand Collaboration to Munich

Eppendorf and BioLabs Expand Collaboration to Munich

The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

read more

Latest News

The New Launch Model for the Agentic Era

The New Launch Model for the Agentic Era

Creating brand value when clinical information is no longer a differentiator The Life Sciences industry is undergoing seismic shifts: expanding drug pipelines, compressed launch timelines, and changing healthcare provider (HCP) and human capital expectations. HCPs...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...

read more
Dementia Relief Through Silence and Brain Wave Modulation

Dementia Relief Through Silence and Brain Wave Modulation

In silence, the brain regenerates, growing new neurons in the hippocampus which is the cerebral center of memory, spatial navigation and emotional regulation (Kriste, Nicola, Kronenberg, Walker, Liu, & Kempermann, 2015). Silence has also been shown to be relaxing...

read more
The Silent Epidemic: Workplace Bullying in Healthcare

The Silent Epidemic: Workplace Bullying in Healthcare

Workplace Bullying in Healthcare and the Leadership Response Healthcare is one of the most demanding professional environments on earth. Clinicians make high-stakes decisions under pressure, routinely absorb the grief and trauma of others, and operate within systems...

read more
Weekly News Roundup | 8 June 2026

Weekly News Roundup | 8 June 2026

Life science news 8 June 2026: ASCO delivers landmark oncology data, GSK achieves hepatitis B functional cure breakthrough, and Servier secures a $2.65 billion rare disease deal in a milestone week for the industry. Revolution Medicines presented full Phase 3 data for...

read more
The Scaling Crisis in Cell and Gene Therapy

The Scaling Crisis in Cell and Gene Therapy

There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...

read more
Clinical Trials Roundup | 05 June 2026

Clinical Trials Roundup | 05 June 2026

Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung...

read more
The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...

read more
Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO

When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...

read more
Dementia Relief Through Silence and Brain Wave Modulation

Dementia Relief Through Silence and Brain Wave Modulation

In silence, the brain regenerates, growing new neurons in the hippocampus which is the cerebral center of memory, spatial navigation and emotional regulation (Kriste, Nicola, Kronenberg, Walker, Liu, & Kempermann, 2015). Silence has also been shown to be relaxing...

read more
The Silent Epidemic: Workplace Bullying in Healthcare

The Silent Epidemic: Workplace Bullying in Healthcare

Workplace Bullying in Healthcare and the Leadership Response Healthcare is one of the most demanding professional environments on earth. Clinicians make high-stakes decisions under pressure, routinely absorb the grief and trauma of others, and operate within systems...

read more
Weekly News Roundup | 8 June 2026

Weekly News Roundup | 8 June 2026

Life science news 8 June 2026: ASCO delivers landmark oncology data, GSK achieves hepatitis B functional cure breakthrough, and Servier secures a $2.65 billion rare disease deal in a milestone week for the industry. Revolution Medicines presented full Phase 3 data for...

read more
The Scaling Crisis in Cell and Gene Therapy

The Scaling Crisis in Cell and Gene Therapy

There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...

read more
Clinical Trials Roundup | 05 June 2026

Clinical Trials Roundup | 05 June 2026

Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung...

read more
The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

The Sourcing Channel Moved East

The Sourcing Channel Moved East

A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...

read more
Parkinson’s Research Field is Approaching a Pivotal Moment

Parkinson’s Research Field is Approaching a Pivotal Moment

Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...

read more
The Emerging Health Tech Driving Globalised Healthcare

The Emerging Health Tech Driving Globalised Healthcare

Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...

read more
PDUFA Date Explained: FDA Drug Approval Deadlines

PDUFA Date Explained: FDA Drug Approval Deadlines

Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning,...

read more
Weekly News Roundup | 1 June 2026

Weekly News Roundup | 1 June 2026

Life science news 1 June 2026: FDA approvals, a landmark obesity pill advance and a $10.5 billion Pfizer partnership define a milestone week for pharma and biotech. The week of 24 to 30 May 2026 delivered a string of significant regulatory milestones, high-value...

read more
The Underestimated Occupational Impact of Pelvic Pain

The Underestimated Occupational Impact of Pelvic Pain

When people think about pelvic pain, they often think about symptoms. Cramping. Heavy bleeding. Fatigue. Bloating. Pain during intimacy. Bladder urgency. What is discussed far less is the occupational impact of pelvic pain: the way pain changes a person’s ability to...

read more
Clinical Trials Roundup | 29 May 2026

Clinical Trials Roundup | 29 May 2026

Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...

read more

Further News

Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...

Zanidatamab Approval Resets First-Line HER2 Gastric Cancer Care

The US Food and Drug Administration cleared two zanidatamab regimens on 25 August 2026. The zanidatamab approval covers first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma. It displaces trastuzumab from a first-line backbone that has...

Leverage Trauma-Informed Care to Enhance Adherence to Safety Interventions

Patient trauma can have a significant impact on the ways in which patients interact with the healthcare environment and with its staff. Many patient behaviors can stem from trauma, including lack of adherence to care plans. In the context of patient safety,...

Robotic Gastrectomy Outperforms Laparoscopic Surgery in Japanese Study

Robotic gastrectomy delivers measurably better perioperative outcomes than conventional laparoscopic surgery for gastric cancer, according to a nationwide analysis of Japanese surgical practice covering more than 22,000 patients. Gastric cancer is the fifth most...

Roche Backs Lean Mass Preservation With $2.3bn Hanmi Obesity Deal

Roche has placed a fresh bet on lean mass preservation, the most contested new frontier in obesity drug development. On 24 August 2026, its Genentech unit licensed an experimental candidate from South Korea’s Hanmi Pharmaceutical. The drug, HM17321, is designed to...

How Sustainability Can Become a Competitive Advantage in Biomanufacturing

Sustainability has become an expectation across the life sciences industry. Regulations are evolving, customers expect more from suppliers, and companies are making increasingly ambitious environmental commitments. Compliance has helped create a common baseline for...

Obesity Drug News: GLP-1 Readouts and Approval Watch

Last updated 25 October 2026 This page is the running record of obesity drug news at Life Science Daily News. It tracks what moved in the obesity and GLP-1 pipeline each month. Entries cover trial readouts, regulatory filings, approvals and label expansions. How this...

Creative Biolabs’ CAR Engineering: Moving Cell Programming Inside the Body

CAR cell therapy has demonstrated that immune cells can be genetically programmed to recognize and attack disease-associated targets. Yet conventional CAR-T therapy generally depends on an elaborate ex vivo workflow involving cell collection, genetic modification,...

Genglycos Gene Therapy Approval Sets New Bar for Rare Metabolic Disease

The Genglycos gene therapy approval gives patients with glycogen storage disease type Ia a new option. The FDA describes it as the first approved treatment for the condition. It is designed to address the underlying cause. The US Food and Drug Administration granted...

AI-Discovered Drugs in 2026: The State of Play

Rentosertib reaches Phase III, Isomorphic Labs raises $2.1 billion, and the EU defers its high-risk AI deadlines. What is still missing for AI-discovered drugs is an approval. AI-discovered drugs entered a different phase in 2026. One molecule has now reached a Phase...

Why Ingredient Research Is Only the Beginning of a Health Product

I spent years formulating low-carbohydrate, low-calorie, high-protein and gluten-free foods. That work taught me a lesson that is easy to miss when a new ingredient has exciting research behind it: an ingredient is not a finished product. A study can tell you that an...

Weekly News Roundup | 24 August 2026

Life science news 24 August 2026: the FDA clears Regeneron’s Pasatru for an ultra-rare bone disorder and grants Ultragenyx the first gene therapy for glycogen storage disease type Ia, authorises the first standalone robotic blood-draw device, and the MHRA opens a...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.